北京若生智能科技有限公司
Drug Database
HO

Hoe-285 (Hoe 285 / Brainorm / Albex 285)

✓ Approved

Sanofi S.A · 小分子 · 小分子

什么是 Hoe-285？

Hoe-285 是一种小分子，由Sanofi S.A研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)、Oral (PO)。

药物档案

商品名Hoe 285, Brainorm, Albex 285
公司Sanofi S.A
药物类别小分子
给药途径Injectable (Others), Intravenous (IV), Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Sanofi S.A

治疗适应症

Hoe-285 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersDelayed ischaemic neurological deficit✓ Approved

相关研究文献

PubMedCancer medicine2026-09-10

A Multivariable Prediction Model for Early Mortality in Multiple Myeloma Patients With Renal Impairment.

Liu Menghan M, Jian Yuan Y, Zhou Huixing H, Jia Jing J et al.

Despite therapeutic advances, early mortality remains a significant challenge in multiple myeloma (MM) patients with renal impairment (RI), with no validated prognostic models currently available for this high-risk subgroup. This multicenter, retrospective study aimed to develop and validate a practical nomogram for predicting early death (< 12 months) using readily accessible clinical parameters. We analyzed data from 285 newly diagnosed MM patients with RI treated between 2007 and 2020, divided into training (n = 222) and validation (n = 63) cohorts. Multivariate analysis identified five independent predictors of early mortality: age > 55 years (OR 3.48, 95% CI 1.10-11.01), serum calcium ≥ 2.5 mmol/L (OR 3.29, 95% CI 1.30-8.29), bone marrow plasma cell percentage ≥ 40% (OR 2.90, 95% CI 1.24-6.77), renal response less than partial response (OR 0.27, 95% CI 0.11-0.65), and hematologic response less than complete response (OR 20.93, 95% CI 4.61-95.10). The developed nomogram demonstrated excellent discrimination (AUC 0.858) and calibration in the training cohort, with consistent performance in validation (AUC 0.747). Risk stratification categorized patients into three distinct prognostic groups with significantly different early mortality rates: Low Risk (1.6%), Mid Risk (13.9%), and High Risk (43.9%). This validated model provides the first practical tool for early mortality risk stratification in MM patients with RI, enabling clinicians to identify high-risk patients who may benefit from more intensive interventions. Further prospective validation is warranted to confirm generalizability.

PMID 42717545
阅读全文 →
PubMedAnnals of medicine2026-09-10

Interpretable four-class machine learning prediction of initial I-131 therapy responses in differentiated thyroid cancer.

Lei Yangyang Y, Mao Yi Y, Zhu Rui R, Luo Zhaoxia Z et al.

Differentiated thyroid carcinoma (DTC) responses to initial post-operative I-131 therapy are heterogeneous. Standard binary models combine incomplete responses into a 'non-excellent' category, obscuring transitional states (indeterminate response [IDR] and biochemical incomplete response [BIR]) and outcome-specific drivers. We developed and validated an interpretable four-class machine learning framework to separate these dynamic trajectories and support pre-therapeutic decisions. Data from 948 DTC patients were partitioned into training (n = 663) and test (n = 285) cohorts, with an independent temporal validation cohort (n=150). Four algorithms (Random Forest [RF], eXtreme Gradient Boosting [XGBoost], Light Gradient Boosting Machine [LightGBM] and Multi-Layer Perceptron [MLP]) were evaluated to predict excellent response (ER), IDR, BIR and structural incomplete response (SIR). Performance was assessed via area under the receiver operating characteristic curve (AUC), calibration curves and decision curve analysis (DCA). Shapley Additive exPlanations (SHAP) and multivariable logistic regression quantified category-specific drivers. Random forest achieved a micro-average AUC of 0.894 (95% CI: 0.842-0.901) in the test cohort and 0.885 (95% CI: 0.832-0.912) in validation. SHAP analysis revealed that pre-treatment stimulated thyroglobulin (pre-sTg) and stimulated thyroglobulin to thyroid-stimulating hormone ratio (LOG(sTg/TSH)) dominated ER, IDR and BIR predictions (pre-sTg peak weight: 31.9% in BIR), whereas diagnostic whole-body scintigraphy (Dx-WBS) was definitive for SIR (45.1% weight). Distant metastasis on Dx-WBS dramatically elevated SIR risk (OR: 171.89); pre-sTg ≥ 10 ng/mL significantly increased both SIR (OR: 7.18) and BIR (OR: 5.48) risks. This four-class framework separates biochemical and structural drivers of post-I-131 responses, providing a practical risk-stratification tool for personalized management before therapy.

PMID 42720506
阅读全文 →
PubMedNaunyn-Schmiedeberg's archives of pharmacology2026-09-09

Berberine inhibits the AcrB efflux pump and synergizes with meropenem against carbapenem-resistant hypervirulent Klebsiella pneumoniae: mechanistic insights and in vivo validation.

Zhou Xinran X, Hu Chunrong C, Tian Jiaming J, Chen Ying Y et al.

From 285 non-duplicate clinical CRKP isolates, 170 were confirmed as carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP); after efflux pump phenotyping by the CCCP inhibition method and carbapenemase exclusion via Carba NP testing combined with multiplex carbapenemase gene PCR, 30 strains with AcrAB-TolC efflux-mediated resistance were selected for mechanistic investigation. Molecular docking revealed berberine binding to the AcrB Distal Binding Pocket (free energy: - 7.5 kcal/mol; hydrogen bond with SER-996, 2.6 Å). Checkerboard assays demonstrated synergistic berberine-meropenem activity against all 30 strains (fractional inhibitory concentration index, FICI: 0.1875-0.500; dimensionless). Nile red assays confirmed AcrB efflux inhibition comparable to PAβN, evidenced by attenuated intracellular fluorescence decay (ΔF/F₀ =  - 9.7% vs. - 52.1% in AcrB-overexpressing controls). RT-qPCR showed berberine suppressed acrB transcription via upregulation of ramR and downregulation of ramA. Combination therapy significantly improved murine survival and bacterial clearance versus monotherapy (log-rank P < 0.001).

PMID 42714471
阅读全文 →
PubMedThe Science of the total environment2026-09-09

Contrasting responses of pollinators to urbanization and local management in urban farms of Havana.

Duarte Sandra S, Desutter-Grandcolas Laure L, Gandara Thibault T, Ropars Lise L et al.

Urban expansion reshapes ecological interactions in agroecosystems, yet its effects on plant-pollinator interactions remain poorly documented in tropical cities. We assessed how landscape urbanization and floral availability affect pollinator interactions across 16 urban farms in Havana, Cuba, along a gradient of impervious cover (38-97%). Farm area (0.01-11.2 ha) and plant richness (21-200 species) decreased significantly with urbanization, including a ∼90% decline in plant richness. In contrast, relative floral abundance showed a slight increase, suggesting management intensity may mitigate the effect of urbanization. We recorded 16,119 interactions involving eight pollinator morpho-groups, with interaction abundance varying substantially across sites (285-1735; a sixfold variation). Small wild bees, ants, and hoverflies consistently declined with urbanization across both years (2023 and 2024), whereas flies showed a positive response. Floral availability consistently enhanced visitation by Apis mellifera and other wild pollinator groups like small wild bees. Other morpho-groups exhibited strong interannual variability, including reversals in response direction to urbanization and floral resources. In 2023, urbanization reduced overall interaction number, while in 2024 the pattern was weaker and more heterogeneous, although several groups still showed negative responses to higher urban cover. Overall, floral resources consistently enhanced interactions, whereas urbanization effects were temporally variable. Our findings highlight contrasting temporal and taxon-specific responses of pollinators to urbanization. Despite high urban pressure, local floral management supports functional pollinator diversity and helps sustain pollination services in tropical urban agroecosystems. These results underscore the importance of integrating landscape planning and pollinator-friendly practices to enhance agroecological resilience under continued urban expansion.

PMID 42715891
阅读全文 →
PubMedCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2026-09-09

Increased Cardiovascular Hospitalizations Associated With Presence of Atrial Fibrillation in Acute Coronary Syndrome Patients: A Double Trouble Situation.

Gencaslan Murat M, Yucel Ceyhun C, Ardıc Mustafa Lutfullah ML, Sumbul Hilmi Erdem HE et al.

In previous studies, atrial fibrillation (AF) has been reported to be common among patients with acute coronary syndrome (ACS), and the presence of AF has been associated with increased mortality and morbidity. However, treatment strategies for both ACS and AF have been continuously updated. The aim of the present study was to determine the prevalence of AF in ACS patients treated according to the most recent guideline recommendations and to evaluate the prognostic significance of AF in this population. In this retrospective cohort study, 285 patients diagnosed with and treated for ACS between 2024 and 2025 were included. The prevalence of AF was determined in this cohort. All patients were followed for at least 1-year. The study endpoint was the occurrence of cardiovascular (CV) mortality and CV-related hospitalizations. AF was identified in 79 patients (28%) with ACS. The mean follow-up duration was 16.5 ± 7.4 months. During follow-up, CV mortality occurred in 37 patients (13%), and CV-related hospitalizations were observed in 97 patients (34%). In regression analysis, left atrial (LA) dimension and smoking status were independently associated with the presence of AF (OR = 1.264, 95% CI: 1.164-1.372, p < 0.001 and OR = 2.318, 95% CI: 1.251-4.295, p = 0.008, respectively). Left ventricular ejection fraction and LA dimension were independently associated with CV mortality (HR = 0.964, 95% CI: 0.936-0.992, p = 0.014 and HR = 1.080, 95% CI: 1.012-1.152, p = 0.020, respectively). In addition, the presence of AF and hypertension were independently associated with CV-related hospitalizations (HR = 1.564, 95% CI: 1.091-2.240, p = 0.015; and HR = 1.686, 95% CI: 1.246-2.240, p = 0.001, respectively). Although the presence of AF in patients with ACS was not independently associated with CV mortality, it was independently associated with CV-related hospitalizations despite contemporary treatment strategies. Therefore, closer follow-up and more intensive management of ACS patients with AF may be necessary to reduce the frequency of CV-related hospitalizations.

PMID 42713888
阅读全文 →
PubMedFrontiers in oncology2026-09-09

Economic burden of cancer care in Lebanon's privately insured population: a seven-year retrospective cohort analysis (2018-2024).

Saleh Shadi S, Makhoul Paul P, Chamandi Rawad R, Abdul-Sater Zahi Z

Cancer imposes a growing economic burden on health systems globally, yet longitudinal, population-level data on cancer care costs within private insurance remain scarce in low- and middle-income countries. Lebanon's private insurance sector, administered through third-party administrators (TPAs), covers a substantial share of the economically active population, yet no published study has characterized its cancer-related economic burden, including during the country's economic contraction since 2019. A retrospective cohort analysis used event-level insurance claims from a leading Lebanese TPA for 2018-2024. Claims carrying an ICD-10 cancer diagnosis code (C or D series, excluding benign neoplasms D10-D36) were processed through a standardized pipeline from event to patient level. Analyses covered demographics, cancer type distribution, treatment and service utilization, cost trends, per-member-per-year (PMPY) expenditure, and a high-cost cohort (HCC) defined as USD 100,000 or more in cumulative costs within any rolling 365-day window. The cohort comprised 16,617 unique cancer patients generating 157,550 claims and USD 239.9 million in total expenditure over seven years. Females accounted for 53.7% of patients; breast cancer was the most prevalent diagnosis (19.7%), in the predominant 40-64-year age group (50.2%). Surgery was the most common treatment modality (29.3%), followed by cancer medicines (24.2%) and radiotherapy (14.9%), yet cancer medicines were the largest cost category (37.8% of spend). Annual expenditure rose from USD 35.7 million (2018) to USD 48.9 million (2024), with a transient compression in 2022. A high-cost cohort of 285 patients (1.7%) accounted for USD 55.1 million (23.0% of spend), led by lung cancer (19.7%). Cancer patient rates rose 24.5% (1,015 to 1,263 per 100,000), and per-member cost rose steeply with age, reaching USD 606 PMPY among patients aged 65+ in 2024 versus USD 15-169 in younger groups; overall PMPY reached USD 111.50, recovering from the 2022 trough. This study provides the first longitudinal, claims-based characterization of cancer care's economic burden in Lebanon's privately insured population. Costs are concentrated in a small, identifiable high-cost subgroup, cancer medicines dominate expenditure despite surgery leading by patient volume, and the per-member burden is rising - an actuarial foundation for designing sustainable, oncology-specific benefit structures.

PMID 42712426
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多Hoe-285